Puma Biotechnology INC (PBYI) Shareholder Sio Capital Management LLC Trimmed Position by $6.28 Million as Shares Declined

March 14, 2018 - By Peter Erickson

Investors sentiment increased to 1.55 in 2017 Q3. Its up 0.34, from 1.21 in 2017Q2. It is positive, as 19 investors sold PBYI shares while 41 reduced holdings. 41 funds opened positions while 52 raised stakes. 35.70 million shares or 3.15% more from 34.61 million shares in 2017Q2 were reported. 4,586 were accumulated by First Trust Advsrs Limited Partnership. Moreover, Quantitative Limited Liability has 0.04% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI). Moreover, Royal National Bank & Trust Of Canada has 0% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 3,274 shares. The New York-based Citigroup has invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Brinker Capital reported 0.01% stake. Barclays Pcl has 0.02% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 187,549 shares. Bancorp Of Montreal Can has invested 0.01% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Rock Springs Cap LP owns 330,000 shares for 1.82% of their portfolio. 1.37 million are held by Partner Fund Mngmt Ltd Partnership. Ellington Gru Ltd Liability Co holds 0.09% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 4,400 shares. Orbimed Advsr Limited Liability Company invested in 2.78% or 2.43 million shares. Emerald Mutual Fund Advisers Tru has 291,146 shares. Amer Intl Grp reported 19,262 shares. Natixis has 6,448 shares. Invesco Limited invested in 0% or 69,879 shares.

Since September 29, 2017, it had 0 insider purchases, and 5 selling transactions for $3.20 million activity. $172,515 worth of stock was sold by Lo Steven on Monday, January 22. Shares for $62,117 were sold by EYLER CHARLES R on Monday, January 22. Shares for $172,515 were sold by BRYCE RICHARD PAUL.

Sio Capital Management Llc decreased its stake in Puma Biotechnology Inc (PBYI) by 65.98% based on its latest 2017Q3 regulatory filing with the SEC. Sio Capital Management Llc sold 52,800 shares as the company’s stock declined 6.09% while stock markets rallied. The institutional investor held 27,221 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $3.26 million, down from 80,021 at the end of the previous reported quarter. Sio Capital Management Llc who had been investing in Puma Biotechnology Inc for a number of months, seems to be less bullish one the $2.79 billion market cap company. The stock increased 0.61% or $0.45 during the last trading session, reaching $74.25. About 542,748 shares traded. Puma Biotechnology, Inc. (NYSE:PBYI) has risen 23.65% since March 14, 2017 and is uptrending. It has outperformed by 6.95% the S&P500.

Sio Capital Management Llc, which manages about $116.75M and $192.73M US Long portfolio, upped its stake in Sage Therapeutics Inc (Put) (NASDAQ:SAGE) by 130,400 shares to 190,400 shares, valued at $11.86M in 2017Q3, according to the filing.

Analysts await Puma Biotechnology, Inc. (NASDAQ:PBYI) to report earnings on May, 9. They expect $-0.72 EPS, up 63.45 % or $1.25 from last year’s $-1.97 per share. After $-1.71 actual EPS reported by Puma Biotechnology, Inc. for the previous quarter, Wall Street now forecasts -57.89 % EPS growth.

More news for Puma Biotechnology, Inc. (NASDAQ:PBYI) were recently published by: Businesswire.com, which released: “Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for …” on February 23, 2018. Businesswire.com‘s article titled: “Puma Biotechnology to Present at Cowen’s Annual Healthcare Conference” and published on March 06, 2018 is yet another important article.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Ratings Coverage

Among 11 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Puma Biotechnology Inc had 60 analyst reports since August 27, 2015 according to SRatingsIntel. JP Morgan maintained the stock with “Overweight” rating in Thursday, May 25 report. The stock has “Overweight” rating by Barclays Capital on Friday, November 10. The company was maintained on Wednesday, January 24 by Bank of America. The rating was maintained by J.P. Morgan on Wednesday, August 9 with “Buy”. The firm earned “Buy” rating on Wednesday, January 24 by Citigroup. The company was maintained on Thursday, July 6 by Stifel Nicolaus. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) has “Buy” rating given on Thursday, November 9 by Cowen & Co. The firm has “Hold” rating by RBC Capital Markets given on Tuesday, January 23. The firm has “Buy” rating given on Friday, November 10 by Citigroup. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) has “Buy” rating given on Wednesday, September 6 by Barclays Capital.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.